I 100% agree with you. I’ve been here since 2015
Post# of 148181
IMO, HIV and mTNBC should be the only two indications that CYDY is funding until a license deal is signed and/or the company receives a milestone payment. GvHD, NASH, and make pattern baldness can wait. Just like HIV, success in those trials will mean little until CYDY gets proper funding and off of the OTC. NP’s salary should be cut as well or at least prevented from further raises. He is no doubt a hard worker and brought leronlimab from a back shelf to near approval, but his choice of financing is sinking the company.